Imago BioSciences, Inc. (IMGO) financial statements (2022 and earlier)

Company profile

Business Address 329 OYSTER POINT BLVD., 3RD FLOOR
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:217,400
Cash and cash equivalents11,226
Short-term investments206,184
Other undisclosed cash, cash equivalents, and short-term investments(10)
Other undisclosed current assets3,904
Total current assets:221,304
Noncurrent Assets
Property, plant and equipment2
Other noncurrent assets3,480
Total noncurrent assets:3,482
TOTAL ASSETS:224,786
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10,092
Accounts payable3,459
Accrued liabilities6,633
Total current liabilities:10,092
Noncurrent Liabilities
Total liabilities:10,092
Stockholders' equity
Stockholders' equity attributable to parent214,694
Common stock3
Additional paid in capital327,387
Accumulated other comprehensive loss(43)
Accumulated deficit(112,653)
Total stockholders' equity:214,694
TOTAL LIABILITIES AND EQUITY:224,786

Income statement (P&L) ($ in thousands)

12/31/2021
Operating expenses(42,524)
Operating loss:(42,524)
Nonoperating income215
Other nonoperating expense(99)
Loss from continuing operations before income taxes:(42,309)
Income tax expense(2)
Net loss available to common stockholders, diluted:(42,311)

Comprehensive Income ($ in thousands)

12/31/2021
Net loss:(42,311)
Comprehensive loss:(42,311)
Other undisclosed comprehensive loss, net of tax, attributable to parent(40)
Comprehensive loss, net of tax, attributable to parent:(42,351)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: